Literature DB >> 9326745

A selective impairment of the IL-2 system in lymphocytes of patients with glioblastomas: increased level of soluble IL-2R and reduced protein tyrosine phosphorylation.

E Ashkenazi1, M Deutsch, R Tirosh, A Weinreb, A Tsukerman, C Brodie.   

Abstract

The occurrence of brain tumors is associated with broad suppression of the immune system function; however, the mechanisms involved in this impairment are not fully characterized. In this study, we have examined mechanisms involved in diminished T lymphocyte reactivity in patients with glioblastomas as compared to patients with other types of brain tumors. We found that the proliferative response of T lymphocytes stimulated with phytohemagglutinin or anti-CD3 was significantly reduced in these patients as compared to patients with meningiomas, oligodendrogliomas and healthy individuals. Stimulated T cells appear to express lower levels of the alpha-subunit (p55) of the IL-2 receptor (IL-2R), and increased levels of soluble IL-2R in cell supernatants, whereas no significant differences were observed in the level of the beta (p75)- or gamma-subunits. In addition, we found that competent T cells of glioblastoma patients exhibit lower levels of tyrosine phosphorylation in response to IL-2 as compared with cells of healthy donors. The decrease in the levels of IL-2 and its receptor was selective since no significant changes were observed in the secretion of other Th1- and Th2-derived cytokines (IFN-gamma and IL-4) and the expression of their respective receptors. These results indicate that the diminished response of T cells obtained from patients with glioblastomas may be due to a selective defect in the production of IL-2 and in the expression of functional IL-2R due to a decreased expression of the membranal IL-2R alpha and to lower levels of tyrosine phosphorylation in response to IL-2.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326745     DOI: 10.1159/000097315

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  11 in total

Review 1.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Immunotherapy for primary brain tumors: no longer a matter of privilege.

Authors:  Peter E Fecci; Amy B Heimberger; John H Sampson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

Review 3.  PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.

Authors:  Taemin Oh; Michael E Ivan; Matthew Z Sun; Michael Safaee; Shayan Fakurnejad; Aaron J Clark; Eli T Sayegh; Orin Bloch; Andrew T Parsa
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

Review 4.  Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.

Authors:  James F Curtin; Gwendalyn D King; Marianela Candolfi; Remy B Greeno; Kurt M Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

5.  Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity.

Authors:  Reza Mirzaei; Susobhan Sarkar; Lauren Dzikowski; Khalil S Rawji; Lubaba Khan; Andreas Faissner; Pinaki Bose; V Wee Yong
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

6.  Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway.

Authors:  Jun Wei; Jason Barr; Ling-Yuan Kong; Yongtao Wang; Adam Wu; Amit K Sharma; Joy Gumin; Verlene Henry; Howard Colman; Waldemar Priebe; Raymond Sawaya; Frederick F Lang; Amy B Heimberger
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

Review 7.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

Review 8.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

9.  Epigenetic biomarkers of T-cells in human glioma.

Authors:  John K Wiencke; William P Accomando; Shichun Zheng; Joe Patoka; Xiaoqin Dou; Joanna J Phillips; George Hsuang; Brock C Christensen; E Andres Houseman; Devin C Koestler; Paige Bracci; Joseph L Wiemels; Margaret Wrensch; Heather H Nelson; Karl T Kelsey
Journal:  Epigenetics       Date:  2012-10-29       Impact factor: 4.528

Review 10.  Combating immunosuppression in glioma.

Authors:  Eleanor A Vega; Michael W Graner; John H Sampson
Journal:  Future Oncol       Date:  2008-06       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.